Jonathan Tugwood

9.5k total citations · 1 hit paper
53 papers, 3.7k citations indexed

About

Jonathan Tugwood is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Jonathan Tugwood has authored 53 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 20 papers in Oncology and 8 papers in Physiology. Recurrent topics in Jonathan Tugwood's work include Peroxisome Proliferator-Activated Receptors (19 papers), Drug Transport and Resistance Mechanisms (11 papers) and Metabolism, Diabetes, and Cancer (7 papers). Jonathan Tugwood is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (19 papers), Drug Transport and Resistance Mechanisms (11 papers) and Metabolism, Diabetes, and Cancer (7 papers). Jonathan Tugwood collaborates with scholars based in United Kingdom, United States and Sweden. Jonathan Tugwood's co-authors include Isabelle Issemann, Richard G.W. Anderson, William L. McPheat, T.C. Aldridge, Rebecca A. Prince, Cliff Elcombe, N.J Woodyatt, Ruth Roberts, Stephen Green and Neil Macdonald and has published in prestigious journals such as Genes & Development, The EMBO Journal and Molecular and Cellular Biology.

In The Last Decade

Jonathan Tugwood

53 papers receiving 3.6k citations

Hit Papers

The mouse peroxisome proliferator activated receptor reco... 1992 2026 2003 2014 1992 250 500 750

Peers

Jonathan Tugwood
Kelli D. Plunket United States
Heidi S. Camp United States
Karen L. MacNaul United States
Isabelle Issemann United Kingdom
Tracey Smith-Oliver United States
John Woods United States
Kelli D. Plunket United States
Jonathan Tugwood
Citations per year, relative to Jonathan Tugwood Jonathan Tugwood (= 1×) peers Kelli D. Plunket

Countries citing papers authored by Jonathan Tugwood

Since Specialization
Citations

This map shows the geographic impact of Jonathan Tugwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Tugwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Tugwood more than expected).

Fields of papers citing papers by Jonathan Tugwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Tugwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Tugwood. The network helps show where Jonathan Tugwood may publish in the future.

Co-authorship network of co-authors of Jonathan Tugwood

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Tugwood. A scholar is included among the top collaborators of Jonathan Tugwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Tugwood. Jonathan Tugwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Robert D., Susana Banerjee, Marcia Hall, et al.. (2020). Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic Oncology. 156(3). 545–551. 18 indexed citations
3.
Fernández‐Gutiérrez, Fabiola, Victoria Foy, Jackie Pierce, et al.. (2017). OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial. Journal of Thoracic Oncology. 12(1). S263–S263. 2 indexed citations
4.
Dive, Caroline, et al.. (2016). Circulating tumor cell eXplants (CDX) to advance small cell lung cancer (SCLC) research and drug development. Journal of Thoracic Oncology. 11(2). S3–S3. 1 indexed citations
5.
Cove-Smith, Laura, Neil Woodhouse, Adam Hargreaves, et al.. (2014). An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity. Toxicological Sciences. 140(1). 3–15. 50 indexed citations
6.
Tonge, Daniel, et al.. (2013). The role of microRNAs in the pathogenesis of MMPi-induced skin fibrodysplasia. BMC Genomics. 14(1). 338–338. 6 indexed citations
7.
Faulkner, Lee, K. Martinsson, Karin Cederbrant, et al.. (2012). The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs. Toxicological Sciences. 127(1). 150–158. 47 indexed citations
8.
Lindblom, Per Henrik, Anna‐Lena Berg, Hui Zhang, et al.. (2011). Tesaglitazar, a Dual PPAR-α/γ Agonist, Hamster Carcinogenicity, Investigative Animal and Clinical Studies. Toxicologic Pathology. 40(1). 18–32. 5 indexed citations
9.
Lü, Pin, Sandrine Prost, Helen Caldwell, et al.. (2007). Microarray analysis of gene expression of mouse hepatocytes of different ploidy. Mammalian Genome. 18(9). 617–626. 56 indexed citations
10.
Alfirevic, Ana, Tracy Mills, Daniel F. Carr, et al.. (2007). Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenetics and Genomics. 17(12). 1091–1100. 34 indexed citations
11.
Hellmold, Heike, Hui Zhang, Jan Andersson, et al.. (2007). Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats. Toxicological Sciences. 98(1). 63–74. 28 indexed citations
12.
Tugwood, Jonathan, et al.. (2003). Genomics and the search for novel biomarkers in toxicology. Biomarkers. 8(2). 79–92. 32 indexed citations
14.
James, Neil H., Jason H. Gill, Richard Brindle, et al.. (1998). Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. Toxicology Letters. 102-103. 91–96. 23 indexed citations
15.
Tugwood, Jonathan, et al.. (1998). Peroxisome Proliferator-Activated Receptor-alpha and the Pleiotropic Responses to Peroxisome Proliferators. Archives of toxicology. Supplement. 20. 377–386. 4 indexed citations
16.
Tugwood, Jonathan, Peter R. Holden, Neil H. James, Rebecca A. Prince, & Ruth Roberts. (1998). A peroxisome proliferator-activated receptor-alpha (PPARα) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARα: implications for species differences in responses to peroxisome proliferators. Archives of Toxicology. 72(3). 169–177. 76 indexed citations
17.
Myers, Kevin A., et al.. (1997). Amino Acid Residues in both the DNA-Binding and Ligand-Binding Domains Influence Transcriptional Activity of the Human Peroxisome Proliferator-Activated Receptor Alpha. Biochemical and Biophysical Research Communications. 239(2). 522–526. 17 indexed citations
18.
Tugwood, Jonathan, et al.. (1996). A Human Peroxisome‐Proliferator‐Activated Receptor‐γ is Activated by Inducers of Adipogenesis, Including Thiazolidinedione Drugs. European Journal of Biochemistry. 239(1). 1–7. 183 indexed citations
19.
Steineger, Hilde Hermansen, Hilde Nebb Sørensen, Jonathan Tugwood, et al.. (1994). Dexamethasone and Insulin Demonstrate Marked and Opposite Regulation of the Steady‐State mRNA Level of the Peroxisomal Proliferator‐Activated Receptor (PPAR) in Hepatic Cells. European Journal of Biochemistry. 225(3). 967–974. 124 indexed citations
20.
Tugwood, Jonathan, et al.. (1992). The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment. Toxicology Letters. 64-65. 131–139. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026